240 related articles for article (PubMed ID: 22585386)
21. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
22. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
23. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients.
Barbera M; Pepe P; Paola Q; Aragona F
Arch Ital Urol Androl; 2012 Dec; 84(4):227-9. PubMed ID: 23427750
[TBL] [Abstract][Full Text] [Related]
24. Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?
Pepe P; Fraggetta F; Galia A; Aragona F
Urol Int; 2012; 89(2):143-7. PubMed ID: 22868485
[TBL] [Abstract][Full Text] [Related]
25. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
Remzi M; Haese A; Van Poppel H; De La Taille A; Stenzl A; Hennenlotter J; Marberger M
BJU Int; 2010 Oct; 106(8):1138-42. PubMed ID: 20346035
[TBL] [Abstract][Full Text] [Related]
26. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Raviv G; Zlotta AR; Janssen Th; Descamps F; Vanegas JP; Verhest A; Schulman CC
Cancer; 1996 May; 77(10):2103-8. PubMed ID: 8640677
[TBL] [Abstract][Full Text] [Related]
27. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
28. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
[TBL] [Abstract][Full Text] [Related]
29. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
[TBL] [Abstract][Full Text] [Related]
30. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
31. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
Naya Y; Ayala AG; Tamboli P; Babaian RJ
Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446
[TBL] [Abstract][Full Text] [Related]
32. Role of PSA and its indices in determining the need for repeat prostate biopsies.
Ukimura O; Durrani O; Babaian RJ
Urology; 1997 Jul; 50(1):66-72. PubMed ID: 9218021
[TBL] [Abstract][Full Text] [Related]
33. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
[TBL] [Abstract][Full Text] [Related]
34. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
35. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
36. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
37. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
38. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.
Busetto GM; De Berardinis E; Sciarra A; Panebianco V; Giovannone R; Rosato S; D'Errigo P; Di Silverio F; Gentile V; Salciccia S
Urology; 2013 Dec; 82(6):1355-60. PubMed ID: 24080222
[TBL] [Abstract][Full Text] [Related]
40. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
